Vericel (VCEL) Long-Term Investments (2019 - 2026)
Vericel (VCEL) reported Long-Term Investments of $65.3 million for Q1 2026, down 21.15% on a YoY basis from $82.8 million in Q1 2025, and up 6.33% sequentially from $61.4 million in Q4 2025.
Vericel (VCEL) Long-Term Investments (2019 - 2026) Analysis & Trends
Vericel (VCEL) has 8 years of Long-Term Investments data on file, last reported at $65.3 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments fell 21.15% year-over-year to $65.3 million; the trailing twelve-month figure through Mar 2026 stood at $65.3 million (down 21.15% YoY), and the FY2025 full-year result was $61.4 million, up 53.95% from the prior year.
- Long-Term Investments improved to $65.3 million in Q1 2026, from $61.4 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $84.6 million in Q3 2025 to a low of $19.9 million in Q1 2023.
- A 5-year average of $46.8 million and a median of $39.9 million in 2024 frame the typical range for Long-Term Investments.
- Across the five-year window, Long-Term Investments slumped 66.03% in 2022 and soared 219.59% in 2023, its largest moves.
- Tracing VCEL's Long-Term Investments over 5 years: stood at $20.0 million in 2022, then grew by 26.66% to $25.3 million in 2023, then soared by 57.73% to $39.9 million in 2024, then soared by 53.95% to $61.4 million in 2025, then advanced by 6.33% to $65.3 million in 2026.
- Business Quant data shows VCEL's Long-Term Investments at $65.3 million in Q1 2026, $61.4 million in Q4 2025, and $84.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 65.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.28 Mn |
| Dec 31, 2025 | 61.40 Mn |
| Sep 30, 2025 | 84.60 Mn |
| Jun 30, 2025 | 47.40 Mn |
| Mar 31, 2025 | 82.80 Mn |
| Dec 31, 2024 | 39.88 Mn |
| Sep 30, 2024 | 32.90 Mn |
| Jun 30, 2024 | 78.30 Mn |
| Mar 31, 2024 | 29.43 Mn |
| Dec 31, 2023 | 25.28 Mn |
| Sep 30, 2023 | 65.10 Mn |
| Jun 30, 2023 | 75.80 Mn |
| Mar 31, 2023 | 19.91 Mn |
| Dec 31, 2022 | 19.96 Mn |
| Sep 30, 2022 | 21.74 Mn |
| Jun 30, 2022 | 23.72 Mn |
| Mar 31, 2022 | 22.80 Mn |
| Dec 31, 2021 | 25.69 Mn |
| Sep 30, 2021 | 64.00 Mn |
| Jun 30, 2021 | 64.00 Mn |